CTI BioPharma Corp. Total Assets 2011-2026 | CTIC

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets CTI BioPharma Corp.

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
126 M	72.4 M	58.2 M	46.3 M	89.8 M	54.9 M	63.8 M	144 M	92.3 M	93.7 M	73.7 M	62.2 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
144 M	46.3 M	81.5 M

Quarterly Total Assets CTI BioPharma Corp.

2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
112 M	126 M	123 M	135 M	131 M	72.4 M	101 M	77.5 M	42.8 M	58.2 M	58.2 M	58.2 M	58.2 M	46.3 M	46.3 M	46.3 M	46.3 M	89.8 M	89.8 M	89.8 M	89.8 M	54.9 M	54.9 M	54.9 M	54.9 M	63.8 M	63.8 M	63.8 M	63.8 M	144 M	144 M	144 M	144 M	92.3 M	92.3 M	92.3 M	92.3 M	93.7 M	93.7 M	93.7 M	93.7 M	73.7 M	73.7 M	73.7 M	73.7 M	62.2 M	62.2 M	62.2 M	62.2 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
144 M	42.8 M	82.4 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Autolus Therapeutics plc AUTL	783 M	$ 1.37	-8.67 %	$ 350 M	Britain
Aeglea BioTherapeutics AGLE	608 M	-	-	$ 1.01 B	USA
Adagene ADAG	89.3 M	$ 1.65	6.11 %	$ 92.9 M	China
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.43	-2.69 %	$ 8.25 B	Australia
Biogen BIIB	28 B	$ 177.93	-4.15 %	$ 25.9 B	USA
Arrowhead Pharmaceuticals ARWR	1.39 B	$ 65.89	-0.06 %	$ 8.81 B	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
AVROBIO AVRO	101 M	-	1083.1 %	$ 745 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
AstraZeneca PLC AZN	104 B	$ 94.4	0.82 %	$ 96.9 B	Britain
BeiGene, Ltd. BGNE	5.92 B	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	23.8 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	226 M	-	-7.31 %	$ 87 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Ascendis Pharma A/S ASND	1.18 B	$ 214.55	2.77 %	$ 5 B	Danmark
Codiak BioSciences CDAK	172 M	-	-55.98 %	$ 2.15 M	USA
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Bristol-Myers Squibb Company BMY	92.6 B	$ 55.84	0.13 %	$ 113 B	USA
Cerevel Therapeutics Holdings CERE	1.24 B	-	-	$ 7.29 B	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Caladrius Biosciences CLBS	35 M	-	-16.75 %	$ 25.8 M	USA
BioLineRx Ltd. BLRX	38.9 M	$ 2.86	-	$ 908 M	Israel
Clearside Biomedical CLSD	34 M	-	-	$ 25.3 M	USA
Chimerix CMRX	213 M	-	-	$ 756 M	USA
Adaptimmune Therapeutics plc ADAP	283 M	-	-15.15 %	$ 60.3 M	Britain
BioNTech SE BNTX	22.5 B	$ 106.88	4.6 %	$ 27.2 B	Germany
Can-Fite BioPharma Ltd. CANF	9.12 M	$ 4.18	-1.65 %	$ 9.1 B	Israel
AIkido Pharma AIKI	47.1 M	-	1.93 %	$ 17.4 M	USA
Catalyst Biosciences CBIO	117 M	$ 11.09	1.0 %	$ 730 M	USA
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
AlloVir ALVR	119 M	-	4.14 %	$ 49.1 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Coherus BioSciences CHRS	630 M	$ 1.69	2.12 %	$ 159 M	USA
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	1.58 B	$ 28.99	-1.39 %	$ 1.4 B	USA
Celldex Therapeutics CLDX	792 M	$ 25.71	0.16 %	$ 1.66 M	USA
Cellectis S.A. CLLS	384 M	$ 4.24	-0.47 %	$ 116 M	France
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
Burford Capital Limited BUR	3.11 B	$ 9.57	-0.78 %	$ 1.55 B	Britain